Document is current
Any future updates will be listed below
-
Authors
Werner, M. H. https://orcid.org/0000-0002-7091-3716
McGarry, A. https://orcid.org/0009-0009-2819-6029
Meyer, C.
Mancino, E.
Klint, C.
Pellecchia, J.
Kieburtz, K. https://orcid.org/0000-0002-1645-6921
Levine, T.
Bellaire, B.
Gibbons, C.
Freeman, R.
Ellenbogen, A.
Klos, K.
Ospina, M.
Hauser, R. A. https://orcid.org/0000-0002-6369-1203
Shannon, K. https://orcid.org/0000-0001-5171-6779
Asaad, H.
Park, A. https://orcid.org/0000-0002-3826-6694
McAllister, P.
Isaacson, S. H.
LeDoux, M. S.
Dhall, R.
Shpiner, D.
Charles, P.
Agarwal, P.
Peckham, E.
Mazzeo, P. https://orcid.org/0009-0002-3816-4783
Davis, M.
Pahwa, R.
Brodsky, M.
Lew, M. https://orcid.org/0000-0001-7906-0388
Purino, L.
Mantri, S.
Parashos, S. https://orcid.org/0009-0003-9565-169X
Justiz, W.
Chachar, M.
Robottom, B.
Budman, E.
Blindauer, K.
Bellows, S.
Goudreau, J.
Steen, S.
Olanow, C. W.
- License Information
-
More Information
Article History
Received: 30 June 2025
Accepted: 2 February 2026
First Online: 20 February 2026
Competing interests
: M.H.W. is the Founder, was Chief Executive and remains a shareholder of Inhibikase Therapeutics, and is the Founder and a shareholder of ABLi Therapeutics. C.M., C.K. and J.P. are, or were, employees and shareholders of Inhibikase Therapeutics, and C.M. is a shareholder of ABLi Therapeutics. C.W.O is the past Chief Executive of Clintrex Research and K. Kieburtz is the current Managing Director of Clintrex. Clintrex Research provides services to many pharmaceutical and biotech companies, including Inhibikase and ABLi. C.W.O. was a shareholder of Inhibikase and served as an expert witness in the paraquat litigation. T.L. is Chief Medical Officer and shareholder of CND Life Sciences. R.F. is a shareholder of CND Life Sciences and Inhibikase Therapeutics, and was a board member of Inhibikase. C.G. is the Chief Scientific Officer of CND Life Sciences and is a shareholder. All other authors declare no competing interests.
